Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2016-03-10 | tolfenamic acid | RV Developpement (France) Nasser H. Zawia (USA - RI) | behavioural variant frontotemporal dementia |
Granting of the orphan status in the US |
2016-02-17 | venetoclax | Abbvie (USA - IL) | acute myeloid leukaemia | Granting of the orphan status in the EU |
2018-09-12 | biosimilar rituximab - biosimilar version of Mabthera®/Rituxan® | Celltrion (Republic of Korea) Teva Pharmaceutical (Israel) |
|
Acceptation for review of a NDA |
2016-04-01 | eribulin | Eisai (Japan) | liposarcoma |
Positive opinion for the granting of a Market Authorisation in the US |
2016-01-07 | dermal regeneration matrix | Integra LifeSciences (USA - NJ) | diabetic foot ulcer |
Granting of a Market Authorisation in the US |
2016-02-05 | daclatasvir in combination with sofosbuvir | BMS (USA - NY) | patients with genotype 1 or genotype 3 chronic hepatitis C with HIV-1 coinfection or advanced cirrhosis, and post-liver transplant HCV recurrence |
Granting of a Market Authorisation in the US |
2016-02-07 | small molecule FGFR4 inhibitor | Blueprint Medicines Corporation (USA – MA) | hepatocellular carcinoma |
Granting of a patent |
2016-01-28 | olaparib | AstraZeneca (UK) | BRCA1/2 or ATM gene mutated metastatic castration resistant prostate cancer (mCRPC) |
Granting of the Breakthrough Therapy status |
2015-01-15 | lentiviral vector pseudotyped by the New Jersey serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins | Theravectys (France) | adult T-cell leukaemia/lymphoma |
Granting of the orphan status in the EU |
2015-03-19 | autologous adipose tissue-derived stromal vascular fraction cells | Assistance Publique Hôpitaux de Marseille - AP-HM (France) | systemic sclerosis |
Granting of a patent |
2015-02-12 | defactinib - N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | Verastem (USA - MA) | ovarian cancer |
Granting of the orphan status in the US |
2015-04-20 | cantrixil | CanTx (USA - CT) | ovarian cancer |
Granting of the orphan status in the US |
2015-12-31 | anlotinib hydrochloride | Advenchen Laboratories (USA - CA) | ovarian cancer |
Granting of the orphan status in the US |
2016-02-03 | multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant | Tapimmune (USA - FL) | ovarian cancer |
Granting of a Fast Track status |
2015-12-31 | 5-imino-13-deoxydoxorubicin HCl | Gem Pharmaceuticals (USA - AL) | soft tissue sarcoma |
Granting of the orphan status in the US |
2015-12-29 | 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl) methoxy)benzaldehyde | Global Blood Therapeutics (USA - CA) | sickle cell disease |
Granting of the orphan status in the US |
2015-05-26 | prasugrel hydrochloride | Eli Lilly (USA -IN) | sickle cell disease |
Granting of the orphan status in the US |
2015-01-15 | pegylated carboxyhemoglobin bovine | Prolong Pharmaceuticals (USA - NJ) | sickle cell disease |
Granting of the orphan status in the US |
2015-12-14 | sirolimus | Rare Partners srl Impresa Sociale (Italy) | beta thalassaemia intermedia and major |
Granting of the orphan status in the EU |
2017-05-10 | doxorubicine Trandrug™ | Onxeo (France) | hepatocellular carcinoma | Granting of a patent |
© 2024 Biopharmanalyses - Powered by Samacom+